Correlação de quimioterapias neoadjuvantes com resposta patológica completa em pacientes com câncer de mama
DOI:
https://doi.org/10.34119/bjhrv8n2-131Keywords:
câncer de mama, quimioterapia neodjuvante, resposta patológica completaAbstract
O câncer de mama (CM) é o segundo câncer mais recorrente nas mulheres. A cada 3 diagnósticos de câncer, 1 é CM, sendo este o que mais causa óbito no mundo entre elas. Entretanto, devido a detecção precoce e aperfeiçoamento no tratamento, houve queda relativa de mortes decorrentes de CM. Dentre os tratamentos, a quimioterapia neoadjuvante (QTneo) é utilizada para melhorar as condições cirúrgicas de pacientes com câncer avançado ou quando há envolvimento linfonodal. Entretanto, dependendo do tipo de tumor e quimioterapia utilizada, esse tratamento pode apresentar uma resposta patológica completa (RPC). Para os cânceres do tipo luminal-B/HER-2+ ou luminal-A esse padrão de resposta completa não é comum. Mas, para tumores do tipo luminal B/HER-2-, HER-2+ e triplo negativo, a RPC é mais encontrada. Contudo, os protocolos quimioterápicos utilizados nessas RPC ainda não são padronizados. Assim, o objetivo desse estudo foi investigar e correlacionar padrões quimioterápicos com RPC de pacientes com CM. Para isso, 100 prontuários de pacientes portadoras de CM do Ambulatório de Saúde da Mulher de Araraquara/SP foram avaliados e observou-se que o CM acomete principalmente mulheres ≥ 40 anos, sendo a raça branca a mais prevalente, o carcinoma ductal invasivo representou maioria dentre os diversos tipos histológico, o tipo molecular mais frequente foi o luminal B, o estadiamento mais encontrado foi o IIIB e o regime quimioterápico mais amplamente empregado foi o de antraciclina + taxano. Porém, não se observou significância estatística na influência de tais variáveis para predizer o desfecho em RPC e resposta patológica incompleta (RPI).
References
ALEXANDER, J. et al. "Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer", Cancers (Basel), Vol. 14, Page 295, v. 14, n. 2, p. 295, 7 jan. 2022. DOI: 10.3390/CANCERS14020295. Disponível em: https://www.mdpi.com/2072-6694/14/2/295/htm. Acesso em: 15 out. 2022.
ANDRADE, D. A. P. DE et al. Quimioterapia neoadjuvante e resposta patológica: coorte retrospectiva. Einstein (São Paulo), v. 11, n. 4, p. 446–450, 2013.
BALMATIVOLA, D. et al. Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Research and Treatment, v. 148, n. 3, p. 511–523, 2014.
BURSTEIN, H. J. "Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer", New England Journal of Medicine, v. 383, n. 26, p. 2557–2570, 24 dez. 2020. DOI: 10.1056/NEJMRA1307118/SUPPL_FILE/NEJMRA1307118_DISCLOSURES.PDF. Disponível em: https://www.nejm.org/doi/10.1056/NEJMra1307118. Acesso em: 15 out. 2022.
CAUDLE, AS. et al. Avaliação axilar aprimorada após terapia neoadjuvante para pacientes com câncer de mama com linfonodos positivos usando avaliação seletiva de linfonodos cortados: implementação de dissecção axilar direcionada. J Clin Oncol 2016; 34 :1072-8. 10.1200/JCO.2015.64.0094.
CHAUDHURY, S. et al. "Breast Cancer Calcifications: Identification Using a Novel Segmentation Approach", Computational and Mathematical Methods in Medicine, v. 2021, 2021. DOI: 10.1155/2021/9905808.
CHOU, H. H. et al. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Biomedical Journal, v. 42, n. 1, p. 66–74, 2019.
COLLINS, P. M. et al. "Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome", The American Journal of Surgery, v. 222, n. 2, p. 368–376, 1 ago. 2021. DOI: 10.1016/J.AMJSURG.2020.11.053.
COOPEY, S. B. "Supraclavicular and Contralateral Axillary Lymph Node Involvement in Breast Cancer Patients", Annals of Surgical Oncology, v. 29, n. 10, p. 6100–6105, 6 jul. 2022. DOI: 10.1245/S10434-022-12134-7. Disponível em: https://link.springer.com/article/10.1245/s10434-022-12134-7. Acesso em: 15 out. 2022.
COSTANTINI, M. et al. "Axillary Nodal Metastases from Carcinoma of Unknown Primary (CUPAx): Role of Contrast-Enhanced Spectral Mammography (CESM) in Detecting Occult Breast Cancer", Journal of Personalized Medicine, Vol. 11, Page 465, v. 11, n. 6, p. 465, 25 maio 2021. DOI: 10.3390/JPM11060465. Disponível em: https://www.mdpi.com/2075-4426/11/6/465/htm. Acesso em: 15 out. 2022.
DE BROT, M. et al. "Basal-like breast cancers: clinicopathological features and outcome", Revista da Associação Médica Brasileira, v. 55, n. 5, p. 529–534, 2009. DOI: 10.1590/S0104-42302009000500014. Disponível em: https://www.scielo.br/j/ramb/a/NyGtChp3FZg7cSz4jWhXyHF/?lang=en. Acesso em: 26 out. 2023.
DERAKHSHAN, F.; REIS-FILHO, J. S. Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, v. 17, n. 1, p. 181–204, 24 jan. 2022.
DEROUANE, F. et al. "Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine", Cancers (Basel), Vol. 14, Page 3876, v. 14, n. 16, p. 3876, 11 ago. 2022. DOI: 10.3390/CANCERS14163876. Disponível em: https://www.mdpi.com/2072-6694/14/16/3876/htm. Acesso em: 15 out. 2022.
DESANTIS, C. E. et al. "International Variation in Female Breast Cancer Incidence and Mortality Rates", Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, v. 24, n. 10, p. 1495–1506, 1 out. 2015. DOI: 10.1158/1055-9965.EPI-15-0535. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26359465/. Acesso em: 15 out. 2022.
DIECI, M. V. et al. "Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial", Clinical Cancer Research, v. 28, n. 2, p. 308–317, 15 jan. 2022. DOI: 10.1158/1078-0432.CCR-21-2260/674021/AM/NEOADJUVANT-CHEMOTHERAPY-AND-IMMUNOTHERAPY-IN. Disponível em: https://aacrjournals.org/clincancerres/article/28/2/308/675607/Neoadjuvant-Chemotherapy-and-Immunotherapy-in. Acesso em: 15 out. 2022.
DUNCAN, A. M. et al. "Anatomy of the Breast Fascial System: A Systematic Review of the Literature", Plastic and Reconstructive Surgery, v. 149, n. 1, p. 28–40, 1 jan. 2022. DOI: 10.1097/PRS.0000000000008671.
GAO, J. J., SWAIN, S. M. "Luminal A Breast Cancer and Molecular Assays: A Review", The Oncologist, v. 23, n. 5, p. 556, 1 maio 2018. DOI: 10.1634/THEONCOLOGIST.2017-0535. Disponível em: /pmc/articles/PMC5947456/. Acesso em: 25 out. 2023.
GINSBURG, O. et al. "Breast cancer early detection: a phased approach to implementation", Cancer, v. 126, n. Suppl 10, p. 2379, 5 maio 2020. DOI: 10.1002/CNCR.32887. Disponível em: /pmc/articles/PMC7237065/. Acesso em: 15 out. 2022.
HOUSSAMI, N. et al. Meta-análise da associação do subtipo de câncer de mama e resposta patológica completa à quimioterapia neoadjuvante. Eur J Cancer. 2012; 48 :3342–3354.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA (INCA). Estimativa 2023: incidência de câncer no Brasil. [s.l: s.n.].
KEELAN, S., FLANAGAN, M., HILL, A. D. K. "Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers", Frontiers in Oncology, v. 11, p. 1608, 4 ago. 2021. DOI: 10.3389/FONC.2021.622621/BIBTEX.
KORDE, L. A. et al. "Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline", Journal of Clinical Oncology, v. 39, n. 13, p. 1485–1505, 1 maio 2021. DOI: 10.1200/JCO.20.03399.
KUTLU, E. et al. Quimioterapia neoadjuvante com ciclofosfamida, mitoxantrona e 5-fluorouracil no câncer de mama localmente avançado. Oncologia 1 de março de 2005; 28 (2): 81–85. https://doi.org/10.1159/000082951.
LEI, S. et al. "Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020", Cancer Communications, v. 41, n. 11, p. 1183, 1 nov. 2021. DOI: 10.1002/CAC2.12207. Disponível em: /pmc/articles/PMC8626596/. Acesso em: 15 out. 2022.
LILLEBORGE, M. et al. "Patterns of aggressiveness: risk of progression to invasive breast cancer by mammographic features of calcifications in screen-detected ductal carcinoma in situ", Acta Radiol, v. 63, n. 5, p. 586–595, 22 abr. 2021. DOI: 10.1177/02841851211006319. Disponível em: https://journals.sagepub.com/doi/abs/10.1177/02841851211006319. Acesso em: 15 out. 2022.
LIPS, E. H. et al. "Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer", Nature Genetics 2022 54:6, v. 54, n. 6, p. 850–860, 9 jun. 2022. DOI: 10.1038/s41588-022-01082-3. Disponível em: https://www.nature.com/articles/s41588-022-01082-3. Acesso em: 15 out. 2022.
ŁUKASIEWICZ, S. et al. "Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review", Cancers, v. 13, n. 17, 1 set. 2021. DOI: 10.3390/CANCERS13174287. Disponível em: /pmc/articles/PMC8428369/. Acesso em: 25 out. 2023.
LV, Y. et al. Factors Affecting Pathological Complete Response After Neoadjuvant Chemotherapy in Operable Primary Breast Cancer. Journal of the College of Physicians and Surgeons Pakistan, v. 30, n. 4, p. 389–393, 1 abr. 2020.
MAMOUNAS, E. P. Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer. Annals of Surgical Oncology, v. 22, n. 5, p. 1425–1433, 2 maio 2015.
MAZOUNI, C. et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007 Jul 1;25(19):2650-5. doi: 10.1200/JCO.2006.08.2271. PMID: 17602071.
NAGAO, T. et al. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289-295. doi:10.1016/j.breast.2011.12.011.
NARAYNSINGH, V. et al. "The Pushing Sign for Early Skin Tethering in Breast Cancer", Cureus, v. 13, n. 12, 16 dez. 2021. DOI: 10.7759/CUREUS.20471. Disponível em: https://www.cureus.com/articles/78723-the-pushing-sign-for-early-skin-tethering-in-breast-cancer. Acesso em: 15 out. 2022.
NAROD, S. A. et al. "Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ", JAMA Oncology, v. 1, n. 7, p. 888–896, 1 out. 2015. DOI: 10.1001/JAMAONCOL.2015.2510. Disponível em: https://jamanetwork.com/journals/jamaoncology/fullarticle/2427491. Acesso em: 15 out. 2022.
PEREZ MA. Et al. Predictive factors for neoadjuvant chemotherapy in locally advanced breast cancer. J Clin Oncol. 2004;22(14 Suppl):91s. Abstract 863.
PRAKASH, I. et al. "Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer", Breast Cancer Research and Treatment, v. 186, n. 2, p. 535–550, 18 nov. 2020. DOI: 10.1007/S10549-020-06012-7. Disponível em: https://link.springer.com/article/10.1007/s10549-020-06012-7. Acesso em: 15 out. 2022.
RAKHA, E., TOSS, M., QUINN, C. "Specific cell differentiation in breast cancer: a basis for histological classification", Journal of Clinical Pathology, v. 75, n. 2, p. 76–84, 1 fev. 2022. DOI: 10.1136/JCLINPATH-2021-207487. Disponível em: https://jcp.bmj.com/content/75/2/76. Acesso em: 15 out. 2022.
RASTOGI, P. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-785. doi:10.1200/JCO.2007.15.0235.
RELATION, T. et al. Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management. Annals of Surgical Oncology, v. 28, n. 11, p. 6489–6497, 2021.
SEMIGLAZOV, V. et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 2011;37(10):856-863. doi:10.1016/j.ejso.2011.07.003.
SIMONS, J. M. et al. "Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study", Breast Cancer Research and Treatment, v. 185, n. 2, p. 441–451, 1 jan. 2021. DOI: 10.1007/S10549-020-05966-Y/FIGURES/4. Disponível em: https://link.springer.com/article/10.1007/s10549-020-05966-y. Acesso em: 15 out. 2022.
SMITH, IE. et al. Tratamento neoadjuvante do câncer de mama pós-menopausa com anastrozol, tamoxifeno ou ambos em combinação: o estudo multicêntrico duplo-cego randomizado Immediate Preoperative Anastrozol, Tamoxifeno ou Combinado com Tamoxifeno (IMPACT). J Clin Oncol. 2005; 23 :5108–5116.
SOKOLOVA, A., LAKHANI, S. R. "Lobular carcinoma in situ: diagnostic criteria and molecular correlates", Modern Pathology, v. 34, n. 1, p. 8–14, 6 out. 2020. DOI: 10.1038/s41379-020-00689-3. Disponível em: https://www.nature.com/articles/s41379-020-00689-3. Acesso em: 15 out. 2022.
SUNG, H. et al. "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries", CA: A Cancer Journal for Clinicians, v. 71, n. 3, p. 209–249, 1 maio 2021. DOI: 10.3322/CAAC.21660. Disponível em: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21660. Acesso em: 15 out. 2022.
TAIRA, N. et al. "Health-Related Quality of Life with Trastuzumab Monotherapy Versus Trastuzumab plus Standard Chemotherapy as Adjuvant Therapy in Older Patients with HER2-Positive Breast Cancer", Journal of Clinical Oncology, v. 39, n. 22, p. 2452–2462, 1 ago. 2021. DOI: 10.1200/JCO.20.02751.
TANG, S. et al. Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer. Gland Surgery, v. 9, n. 5, p. 1415–1427, 2020.
TEE, SR. et al. Meta-análise de biópsia de linfonodo sentinela após quimioterapia neoadjuvante em pacientes com câncer de mama positivo para linfonodo comprovado por biópsia inicial. Br J Surg 2018; 105 :1541-52. 10.1002/bjs.10986.
TERMAN, E. et al. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Research and Treatment, v. 200, n. 1, p. 75–83, 2023.
TRAPANI, D. et al. "Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review", Breast Cancer Research and Treatment, v. 187, n. 2, p. 323–337, 27 maio 2021. DOI: 10.1007/S10549-021-06259-8. Disponível em: https://link.springer.com/article/10.1007/s10549-021-06259-8. Acesso em: 15 out. 2022.
VAN MAAREN, M. C. et al. "Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis", The Breast, v. 59, p. 376–382, 1 out. 2021. DOI: 10.1016/J.BREAST.2021.07.020.
VIEIRA, C. C. et al. "Microinvasive ductal carcinoma in situ: clinical presentation, imaging features, pathologic findings, and outcome", European journal of radiology, v. 73, n. 1, p. 102–107, jan. 2010. DOI: 10.1016/J.EJRAD.2008.09.037. Disponível em: https://pubmed.ncbi.nlm.nih.gov/19026501/. Acesso em: 15 out. 2022.
VON MINCKWITZ, G. et al. "Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes", Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v. 30, n. 15, p. 1796–1804, 20 maio 2012. DOI: 10.1200/JCO.2011.38.8595. Disponível em: https://pubmed.ncbi.nlm.nih.gov/22508812/. Acesso em: 15 out. 2022.
WAKS, A. G., WINER, E. P. "Breast Cancer Treatment: A Review", JAMA, v. 321, n. 3, p. 288–300, 22 jan. 2019. DOI: 10.1001/JAMA.2018.19323. Disponível em: https://jamanetwork.com/journals/jama/fullarticle/2721183. Acesso em: 15 out. 2022.
WANG, M. et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. Scientific Reports, v. 7, n. July 2016, p. 1–7, 2017.
ZHANG, Y. et al. "Molecular alterations differentiate microinvasive carcinoma from ductal carcinoma in situ and invasive breast carcinoma: retrospective analysis of a large single-center series", International Journal of Clinical and Experimental Pathology, v. 14, n. 8, p. 892, 2021. Disponível em: /pmc/articles/P
